C12Y 207/11
Protein-serine/threonine kinases
Official title: Protein-serine/threonine kinases (2.7.11)
C12Y207/11 (Protein-serine/threonine kinases) appears on 588 US grants and 1,244 published applications in this corpus.
Search patents in C12Y- Granted patents
- 588
- Published applications
- 1,244
- Assignees
- 553
- Inventors
- 2,226
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 2 | 0 |
| 1998 | 4 | 0 |
| 1999 | 9 | 0 |
| 2000 | 6 | 0 |
| 2001 | 8 | 1 |
| 2002 | 11 | 13 |
| 2003 | 4 | 20 |
| 2004 | 4 | 31 |
| 2005 | 1 | 52 |
| 2006 | 3 | 10 |
| 2007 | 0 | 18 |
| 2008 | 5 | 19 |
| 2009 | 9 | 28 |
| 2010 | 15 | 40 |
| 2011 | 16 | 27 |
| 2012 | 16 | 29 |
| 2013 | 12 | 40 |
| 2014 | 16 | 37 |
| 2015 | 34 | 72 |
| 2016 | 33 | 89 |
| 2017 | 48 | 78 |
| 2018 | 38 | 60 |
| 2019 | 46 | 77 |
| 2020 | 45 | 72 |
| 2021 | 56 | 61 |
| 2022 | 34 | 84 |
| 2023 | 31 | 75 |
| 2024 | 25 | 86 |
| 2025 | 29 | 75 |
| 2026 | 28 | 50 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12Y 207/11001Non-specific serine/threonine protein kinase , i.e. casein kinase or checkpoint kinase265
- C12Y 207/11013Protein kinase c73
- C12Y 207/1103Receptor protein serine/threonine kinase50
- C12Y 207/11022Cyclin-dependent kinase46
- C12Y 207/11024Mitogen-activated protein kinase , i.e. mapk or mapk2 or c-jun n-terminal kinase40
- C12Y 207/11021Polo kinase19
- C12Y 207/11025Mitogen-activated protein kinase kinase kinase , i.e. mapkkk or map3k19
- C12Y 207/11011Camp-dependent protein kinase18
All 33 subgroupsShow fewer
- C12Y 207/11017Ca2+/calmodulin-dependent protein kinase16
- C12Y 207/1101Ikappab kinase13
- C12Y 207/11026Tau-protein kinase13
- C12Y 207/11023[rna-polymerase-subunit] kinase5
- C12Y 207/11016G-protein-coupled receptor kinase4
- C12Y 207/11031[hydroxymethylglutaryl-coa reductase ] kinase4
- C12Y 207/11002[pyruvate dehydrogenase ] kinase2
- C12Y 207/11009Goodpasture-antigen-binding protein kinase2
- C12Y 207/11015[beta-adrenergic-receptor] kinase2
- C12Y 207/11018Myosin-light-chain kinase2
- C12Y 207/11012Cgmp-dependent protein kinase1
- C12Y 207/11014Rhodopsin kinase1
- C12Y 207/11027[acetyl-coa carboxylase] kinase1
- C12Y 207/11003Dephospho-[reductase kinase] kinase0
- C12Y 207/11004[3-methyl-2-oxobutanoate dehydrogenase ] kinase0
- C12Y 207/11005[isocitrate dehydrogenase ] kinase0
- C12Y 207/11006[tyrosine 3-monooxygenase] kinase0
- C12Y 207/11007[myosin-heavy-chain] kinase0
- C12Y 207/11008Fas-activated serine/threonine kinase0
- C12Y 207/11019Phosphorylase kinase0
- C12Y 207/1102Elongation factor 2 kinase , i.e. eef-2k0
- C12Y 207/11028Tropomyosin kinase0
- C12Y 207/11029[low-density-lipoprotein receptor] kinase0
- C12Y 207/11032[pyruvate, phosphate dikinase] kinase0
- C12Y 207/11033[pyruvate, water dikinase] kinase0
Recent patents
- Bifunctional antagonists of activin and tumor necrosis factor alpha and uses thereof11 Aug 2026US 12,703,742 B2
- Muscle targeting complexes and formulations for treating myotonic dystrophy4 Aug 2026US 12,697,394 B2Dyne Therapeutics, Inc.
- JNK3 inhibitory peptides4 Aug 2026US 12,698,312 B2Universita' Degli Studi Di Milano
- Methods for inducing cell division of postmitotic cells23 Jun 2026US 12,661,384 B2The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
- Microorganisms for diterpene production23 Jun 2026US 12,662,680 B2Cargill, Incorporated
- Formulations comprising recombinant aav and methods of administering the same8 Oct 2026US 2026/0306663 A1Ultragenyx Pharmaceutical Inc.
- Precision immunosuppression as prevention and therapy for graft-versus-host disease8 Oct 2026US 2026/0308592 A1
- Compositions and methods for the treatment of disorders related to cdkl5 deficiency1 Oct 2026US 2026/0295084 A1Voyager Therapeutics, Inc.
- Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression1 Oct 2026US 2026/0297587 A1Ionis Pharmaceuticals, Inc.
- Plk1 target phosphorylation status and treatment of cancer with plk1 inhibitors1 Oct 2026US 2026/0297646 A1Cardiff Oncology, Inc.
Most cited
By later US patents
- Modified polynucleotides for reducing off-target effects in RNA interference144US 7,595,387 B2Dharmacon, Inc. · 2009
- Interfering RNA molecules134US 7,452,987 B2Silence Therapeutics GmbH · 2008
- Methods and compositions for generating bioactive assemblies of increased complexity and uses128US 7,534,866 B2IBC Pharmaceuticals, Inc. · 2009
- ActRII receptor polypeptides, methods and compositions121US 7,709,605 B2Acceleron Pharma Inc. · 2010
- Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses117US 7,550,143 B2IBC Pharmaceuticals, Inc. · 2009